



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/052,879	10/22/2001	Lesley J. Murray	4-127-1027B

CONFIRMATION NO. 1807

001095

THOMAS HOXIE
NOVARTIS CORPORATION
PATENT AND TRADEMARK DEPT
564 MORRIS AVENUE
SUMMIT, NJ 079011027

FORMALITIES LETTER



OC00000007893946

Date Mailed: 04/18/2002

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
 - Papers contain improper margins. *Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")*
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
-

*A copy of this notice **MUST** be returned with the reply.*

M - Marshall

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



03 CO

CASE 4-127-1027B/D1C1

CERTIFICATE OF MAILING

I hereby certify that the paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Box Missing Parts, 2011 South Clark Place, Crystal Plaza 2 - 8th Floor, Arlington, Virginia 22202.

Marcia Rossell

Type or print name

Signature

May 8, 2002

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Murray et al.

Application No. 10/052,879

Filed: October 22, 2001

For: Methods for Use of Mp1 Ligands with
Primitive Human Stem Cells

FILED: JULY 27, 1999

FOR: NOVEL GENES IN THE CONTROL OF HEMATOPOIESIS

Art Unit: TBA

Examiner: TBA

Confirmation No.: 1807

Docket: 4-127-1027B

Commissioner for Patents
BOX MISSING PARTS
Crystal Plaza 2 - 8th Floor
2011 South Clark Place
Arlington, VA 22202

TRANSMITTAL LETTER

Sir:

Enclosed please find the following:

- a) Preliminary Amendment and Sequence Statement Under 37 CFR §§1.821-1.825;
- b) Substitute Specification;
- c) Substitute paper Sequence Listing;
- d) Copy of Notice to File Corrected Application Papers; and
- e) Return postcard.

The Commissioner is hereby authorized to charge any fees that may be required by this transmittal letter, or to credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(301) 258-4715

Date: May 8, 2002